A detailed history of Cathie Wood (Ark Investment Management LLC) transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ark Investment Management LLC holds 10,989,282 shares of NTLA stock, worth $288 Million. This represents 2.16% of its overall portfolio holdings.

Number of Shares
10,989,282
Previous 11,412,449 3.71%
Holding current value
$288 Million
Previous $348 Million 13.12%
% of portfolio
2.16%
Previous 2.09%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 18, 2024

SELL
$23.82 - $32.8 $10.1 Million - $13.9 Million
-423,167 Reduced 3.71%
10,989,282 $302 Million
Q4 2023

Jan 17, 2024

BUY
$23.16 - $32.34 $33.9 Million - $47.3 Million
1,463,820 Added 14.71%
11,412,449 $348 Million
Q3 2023

Oct 18, 2023

BUY
$31.62 - $45.78 $13.4 Million - $19.4 Million
422,698 Added 4.44%
9,948,629 $315 Million
Q2 2023

Jul 10, 2023

SELL
$34.58 - $46.03 $10.8 Million - $14.3 Million
-311,235 Reduced 3.16%
9,525,931 $388 Million
Q1 2023

Apr 17, 2023

BUY
$33.3 - $44.82 $13.9 Million - $18.7 Million
416,384 Added 4.42%
9,837,166 $367 Million
Q4 2022

Jan 24, 2023

SELL
$33.21 - $62.69 $7.85 Million - $14.8 Million
-236,270 Reduced 2.45%
9,420,782 $0
Q3 2022

Oct 17, 2022

BUY
$53.92 - $71.7 $7.68 Million - $10.2 Million
142,472 Added 1.5%
9,657,052 $540 Million
Q2 2022

Jul 11, 2022

BUY
$38.49 - $76.21 $20.5 Million - $40.7 Million
533,551 Added 5.94%
9,514,580 $439 Million
Q1 2022

Apr 19, 2022

BUY
$58.27 - $118.99 $62 Million - $127 Million
1,064,147 Added 13.44%
8,981,029 $653 Million
Q4 2021

Jan 28, 2022

BUY
$100.76 - $138.36 $118 Million - $162 Million
1,173,326 Added 17.4%
7,916,882 $936 Million
Q3 2021

Nov 12, 2021

SELL
$132.37 - $176.78 $125 Million - $166 Million
-940,885 Reduced 12.24%
6,743,556 $905 Million
Q2 2021

Aug 05, 2021

SELL
$60.88 - $161.91 $117 Million - $312 Million
-1,927,470 Reduced 20.05%
7,684,441 $1.24 Billion
Q1 2021

May 13, 2021

SELL
$46.59 - $83.68 $73.6 Million - $132 Million
-1,579,759 Reduced 14.12%
9,611,911 $771 Million
Q4 2020

Feb 12, 2021

SELL
$18.83 - $63.53 $4.01 Million - $13.5 Million
-213,082 Reduced 1.87%
11,191,670 $609 Million
Q3 2020

Oct 30, 2020

BUY
$17.47 - $24.93 $23,986 - $34,228
1,373 Added 0.01%
11,404,752 $227 Million
Q2 2020

Aug 11, 2020

BUY
$11.14 - $22.87 $13 Million - $26.6 Million
1,164,093 Added 11.37%
11,403,379 $240 Million
Q1 2020

May 14, 2020

BUY
$9.44 - $15.58 $14.1 Million - $23.3 Million
1,497,854 Added 17.14%
10,239,286 $125 Million
Q4 2019

Jan 31, 2020

BUY
$10.43 - $17.67 $2.83 Million - $4.79 Million
270,856 Added 3.2%
8,741,432 $128 Million
Q3 2019

Nov 12, 2019

BUY
$13.07 - $18.51 $2.97 Million - $4.21 Million
227,411 Added 2.76%
8,470,576 $113 Million
Q2 2019

Jul 30, 2019

BUY
$13.88 - $18.41 $3.64 Million - $4.82 Million
261,967 Added 3.28%
8,243,165 $135 Million
Q1 2019

May 13, 2019

BUY
$12.79 - $17.62 $15.1 Million - $20.8 Million
1,179,246 Added 17.34%
7,981,198 $136 Million
Q4 2018

Feb 01, 2019

BUY
$11.39 - $27.13 $11.9 Million - $28.4 Million
1,048,162 Added 18.22%
6,801,952 $92.8 Million
Q3 2018

Nov 07, 2018

BUY
$25.78 - $32.6 $32 Million - $40.4 Million
1,240,206 Added 27.48%
5,753,790 $165 Million
Q2 2018

Aug 07, 2018

BUY
$20.02 - $30.79 $18.2 Million - $28 Million
910,608 Added 25.27%
4,513,584 $123 Million
Q1 2018

May 14, 2018

BUY
$19.43 - $34.95 $43.3 Million - $77.9 Million
2,227,827 Added 162.01%
3,602,976 $76 Million
Q4 2017

Feb 12, 2018

BUY
$17.39 - $31.12 $17.4 Million - $31.2 Million
1,002,671 Added 269.19%
1,375,149 $26.4 Million
Q3 2017

Nov 09, 2017

BUY
$15.16 - $25.75 $3 Million - $5.09 Million
197,668 Added 113.08%
372,478 $9.26 Million
Q2 2017

Aug 11, 2017

BUY
N/A
94,960 Added 118.92%
174,810 $2.8 Million
Q1 2017

May 15, 2017

BUY
N/A
53,306 Added 200.82%
79,850 $1.13 Million
Q4 2016

Feb 13, 2017

BUY
N/A
26,544
26,544 $348,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.99B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track Cathie Wood's Portfolio

Track Cathie Wood Portfolio

Follow Cathie Wood (Ark Investment Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.